Anticancer Potential of Betulonic Acid Derivatives

Adelina Lombrea 1,2, Alexandra Denisa Scurtu 2,3,* , Stefana Avram 1,2, Ioana Zinuca Pavel 1,2, Māris Turks 4, Jevgenija Luginina 4, Uldis Peipinš 5, Cristina Adriana Dehelean 2,3, Codruta Soica 2,6 and Corina Danciu 1,2

Abstract: Clinical trials have evidenced that several natural compounds, belonging to the phytochemical classes of alkaloids, terpenes, phenols and flavonoids, are effective for the management of various types of cancer. Latest research has proven that natural products and their semisynthetic variants may serve as a starting point for new drug candidates with a diversity of biological and pharmacological activities, designed to improve bioavailability, overcome cellular resistance, and enhance therapeutic efficacy. This review was designed to bring an update regarding the anticancer potential of betulonic acid and its semisynthetic derivatives. Chemical derivative structures of betulonic acid including amide, thiol, and piperidine groups, exert an amplification of the in vitro anticancer potential of betulonic acid. With the need for more mechanistic and in vivo data, some derivatives of betulonic acids may represent promising anticancer agents.

Keywords: pentacyclic triterpenes; betulonic acid derivatives; natural compounds; proliferation; apoptosis; in vitro; in vivo; cancer

1. Introduction. Natural Compounds in the Management of Different Types of Cancer

The extensive research over the past decades has identified an increased number of natural compounds from various medicinal plants that elicit chemopreventive potential. These phytochemicals represent an important potential source of anticancer molecules as well as molecular and pharmacological properties that favor such development [6].

These include a wide variety of classes of molecules including alkaloids, terpenes, phenols, flavonoids, and others. These compounds are often potent chemopreventive agents, and the challenge lies in developing them into effective chemotherapeutics that target cancer cells with minimal impact on normal cells [7].

Cancer is one of the largest causes of mortality in the world and due to its prevalence, the discovery of novel anticancer drugs has great importance. Plants, microorganisms, and marine organisms are considered valuable sources for the discovery of anticancer drugs [4,5].

Throughout history, natural products and their derivatives have proved to be useful for the development of chemotherapeutics, presenting a great structural diversity as well as molecular and pharmacological properties that favor such development [6].
Plants have a long history of use in the treatment of cancer. Numerous classes of natural compounds such as alkaloids, terpenes, phenols, and flavonoids have been shown to be effective in clinical trials [7]. Vinca alkaloids: vincristine, vinblastine, vindesine, and vinorelbine isolated from *Vinca rosea* L. (*Apocynaceae*), were the first agents to advance into clinical use. At low doses, they interrupt microtubular activity, whereas, at higher doses, they cause cell cycle arrest and apoptosis [8,9]. Vinca alkaloids have been licensed by the Food and Drug Administration (FDA) as a pharmaceutical treatment against different tumors (leukemia, Hodgkin’s lymphoma, lung cancer, breast cancer) [10]. Five vinca alkaloids are actually in clinical usage: vinblastine and vincristine were approved by the FDA in 1961 and 1963, respectively; the semi-synthetic derivatives vindesine and vinorelbine were approved by the FDA in 1994, and vinflunine, a synthetic derivative, was approved by EMA (European Medicines Agency) in 2012 for treatment of metastatic and advanced urothelial cancer [11,12]. Moreover, in 2019, World Health Organization included vincristine, vinblastine, and vinorelbine on the list of essential medicines for treating Hodgkin lymphoma, Kaposi sarcoma, testicular germ cell tumor, ovarian germ cell tumor, follicular lymphoma, retinoblastoma, rhabdomyosarcoma, Ewing sarcoma, acute lymphoblastic leukemia, non-small cell lung cancer, and metastatic breast cancer [13].

The alkaloid piperine, isolated from the fruits of *Piper nigrum* L. in combination with curcumin, is involved in an ongoing phase I clinical trial for the treatment of bladder cancer [14]. Also, camptothecin, a quinoline alkaloid isolated especially from the stem and bark of *Camptotheca acuminata* Decne, has completed phase III clinical trials for the treatment of pancreatic, ovarian, and colorectal cancers [15]. Currently, irinotecan and topotecan are the two FDA-licensed semi-synthetic camptothecin derivatives and are clinically active and less harmful than the parent compound. Irinotecan is used for advanced cancers of the large intestine and rectum. Topotecan is approved for the treatment of recurrent ovarian cancer, small cell lung cancer, and cancer of the cervix [16].

Terpenes are another class of natural compounds introduced in clinical trials. Ursolic acid, a pentacyclic triterpenoid widely found in different species of plants, has completed phase II clinical trials for the treatment of solid tumors [17]. Paclitaxel, a diterpenoid, isolated from the bark of *Taxus brevifolia* Nutt and its derivatives such as nanopaclitaxel and docetaxel have completed phases I, II, III, and IV of clinical trials for the treatment of breast, ovarian, and endometrial cancers [18,19]. The FDA approved paclitaxel for the treatment of refractory ovarian cancer in 1992, refractory breast cancer in 1994, Kaposi’s sarcoma in 1997, and non-small cell lung cancer in 1998. Docetaxel, a semi-synthetic derivative of paclitaxel, showed greater effectiveness than paclitaxel in certain instances. The FDA authorized docetaxel for the treatment of advanced breast cancer in 1996, non-small pulmonary cancer in 1999, metastatic hormone-refractory prostate cancer in 2004, and head and neck cancer in 2006 [20]. Several of the paclitaxel analogs, such as larafoxin, milataxel, ortataxel, and tesetaxel, are currently under investigation in clinical trials [16].

Lycopene, a carotenoid type terpene, majorly found in red fruits and vegetables, has completed phase II clinical trial for the treatment of hormone-resistant prostate cancer in combination with docetaxel [21,22]. Currently, lycopene is in phase II regarding its effectiveness to reduce skin toxicity in patients with colorectal carcinoma treated with panitumumab [23].

Among phenolic compounds, one of the largest classes of plant secondary metabolites, curcumin, isolated from *Curcuma* plant species, has completed phase I clinical trials for treating metastatic breast cancer in co-therapy with docetaxel [24]. Moreover, curcumin along with paclitaxel has demonstrated efficacy and safety in phase II clinical trials in patients with advanced, metastatic breast cancer [25]. Currently, this phenolic compound is involved in phase III clinical trials regarding its potential to reduce cancer progression in patients with low-risk prostate cancer under active surveillance [26]. Chlorogenic acid has passed phase I clinical study for treating malignant gliomas. The findings revealed that monotherapy of chlorogenic acid in patients with advanced malignancies was effective and well-tolerated for long-term use. Interestingly, for subjects treated with chlorogenic acid,
the median overall survival with grade IV gliomas was 21.4 months, while the globally recognized median overall survival was just 3–4.6 months for subjects at this point [27].

Flavonoids are secondary metabolites commonly found in plants [28]. Flavonoids are usually found in citrus fruits, berries, legumes, green tea, as well as in red wine [29]. Genistein along with cholecalciferol has completed phase II clinical trials treating patients with early-stage prostate cancer [30]. Quercetin is classified as a flavonol and is currently involved in an ongoing phase I trial, which is evaluating its impact on green tea polyphenol absorption in the prostate tissue from patients with prostate cancer [31,32]. Moreover, quercetin is also involved in an ongoing phase II clinical trial regarding its chemopreventive activity in the development of squamous cell carcinoma in patients with Fanconi anemia [33].

Although there are many studies on betulin and betulinic acid [34,35], this review focuses on betulonic acid and, more specifically, on its derivatives, which have also shown important therapeutic effects, thus suggesting their further thorough research.

2. An Overview of the Biologic Activity of Pentacyclic Triterpenes

To date, more than 20,000 triterpenes have been isolated [36]. Triterpenoids are originally synthesized by plants as metabolites and are abundantly present in most medicinal plants in the form of free acids or aglycones. Triterpenes are a diverse group of natural compounds, classified into two main groups: tetracyclic and pentacyclic triterpenes. The class of tetracyclic triterpenes includes compounds such as: euphol, oleandrin, and cucurbitacin. The class of pentacyclic triterpenoids (PT) is richer in structures representative for their biological activity, lupane, oleane, and ursane scaffolds being the main groups of this class. Important phytocompounds due to their biological activity and belonging to the category of pentacyclic triterpenoids are: lupeol, betulin, betulinic acid, betulonic acid (lupane structure), oleanolic acid, maslinic acid (oleanane structure), ursolic acid, and ursolic acid (ursane structure) (Figure 1), nevertheless other such categories including hopane, serratane, friedelane, and taraxane can also be referred [37–39].

![Figure 1. Biologically active pentacyclic triterpenoids in the management of different types of cancer.](image-url)
Secondary plant metabolites such as PT are generated through the cyclization of squalene [40]. Lupeol, oleanane, and ursane structures were found in a variety of plant parts such as bark, cork, leaf, or fruit cuticular wax [41]. Moreover, pentacyclic triterpenes have been detected in edibles such as mango, apple peel, strawberries, pear peel, green pepper, guava, mulberry, or olives, but also in herbal plants such as rosemary, oregano, basil, and lavender. The individual natural human consumption of triterpenes is reported to be approximately 250 mg per day in the Western world and 400 mg per day in Mediterranean countries [42]. However, small quantities, estimated to be under 0.1% of the dry weight of the plant organ, are found in plants. Even so, few plants are considered to have elevated amounts of pentacyclic triterpenes, above 1% of the dry weight of the plant. The highest pentacyclic terpene content has been noticed in the outer bark of the white birch tree (up to 34% [w/w] in betulin) [40]. Furthermore, the leaves from Rosmarinus officinalis L., Olea europaea L., Coffea arabica L., the sapling from Viscum album L., the bark from Platanus L., and the fruit peels from Malus domestica Mill. produce more than 1% (w/w) pentacyclic triterpenes. Due to this property, these plants are useful for obtaining triterpene dry extracts which contain 50–90% (w/w) triterpenes [43].

Natural PT have a broad range of biological activities. Intense pharmacological researches have been conducted on natural PT in order to exploit their medicinal value and mechanism of action. In general, the bioactivities of these phytocompounds have been shown to include antitumor [40,44,45], antiviral [46], antidiabetic [47], anti-inflammatory [48], antimicrobial [49], antiparasitic [39], cardio-protective [50], hepato-protective [51], wound healing properties [52], and others. For example, oleanolic acid, glycyrrhizin, glycyrrhetinic acid, ursoic acid, betulin, betulinic acid, and lupeol increase the absorption of glucose, enhance insulin secretion, boost glucose uptake in peripheral organs, and contribute to the treatment of diabetes and its vascular complications [53]. Zhang et al. tested the inhibitory activity of oleanane-, ursane- and lupane-type triterpenes against α-amylase and yeast α-glucosidase. Results have shown that, in comparison to the IC_{50} value of acarbose (5.3 µM), ursoic acid exerted the highest inhibition of α-amylase, with an IC_{50} value of 22.6 µM, followed by corosolic acid and oleanolic acid with IC_{50} values of 31.2 µM and 94.1 µM, respectively. Regarding the α-glucosidase inhibition, ursoic acid, betulinic acid, and corosolic acid displayed a stronger inhibitory activity than acarbose (IC_{50} = 2479 µM) with IC_{50} levels of 12.1 µM, 14.9 µM, and 17.2 µM, respectively. It appears that the variety of structural skeletons of pentacyclic triterpenes had a substantial effect on the inhibition of α-amylase activity. The fact that ursoic acid displayed stronger α-amylase inhibition than oleanolic acid may be attributed to the shift of the C-29 methyl group from C-20 and C-19. The study found that betulinic acid inhibited α-glucosidase with comparable effectiveness to ursoic acid, indicating that the disparity between ursane and lupane had no major effect on the enzyme inhibition [54]. Numerous experiments have shown that different PT have antidiabetic properties in healthy or diabetic animal models. Phanoside (a dammarane-type structure) at a dosage of up to 500 µM exerted significant effects on insulin secretion in rat pancreatic cells. In INS-1 832/13 pancreatic β-cells, oleanolic acid (50 µM) improved insulin secretion. Moreover, in isolated rat islets, oleanolic acid (30 µM) also improved insulin secretion, which was stimulated by high glucose levels [55,56]. The plasma insulin levels of Wistar rats were improved by ginsenoside Rh2 (1.0 mg/kg) and oleanolic acid (5, 10 and 20 mg/kg) by freeing acetylcholine (ACh) from nerve terminals and then activating M3 muscarinic receptors in pancreatic cells [57,58].

Furthermore, PT showed anti-inflammatory, antioxidant, anti-adiposity, and cardioprotective properties in high-carbohydrate high-fat diet-induced metabolic syndrome [59,60]. In addition, the weight-reducing effects of PT are due to the downregulation of pro-inflammatory cytokines, insulin resistance, oxidative stress, and total fatty acids, all of these contributing to a more efficient glycemic regulation [61]. In the study performed by Tang et al., they have demonstrated that betulin at 3 µg/mL incubated for 6 h suppressed the maturation of sterol regulatory element-binding proteins (SREBP) and reduced cholesterol and fatty acid biosynthesis in rat hepatocytes CRL-1601. At a dosage of 30 mg/kg/day
for 6 weeks, betulin has lowered serum and tissue lipid levels, helped improve glucose tolerance, and tended to increase insulin sensitivity in C57BL/6j mice fed with Western-style diet. In addition, the application of betulin to the LDLR-knockout mice model of atherosclerosis disease has revealed its ability to decrease the size of the atherosclerotic plaques [62]. As well as betulin, betulinic acid (50 mg/kg for 15 weeks) lowered body weight, blood glucose, abdominal fat, plasma triglycerides, and total cholesterol levels in Swiss mice fed with a high-fat diet. Interestingly, betulinic acid treatment further decreased the circulating level of the orexigenic hormone ghrelin and increased the anorexigenic hormone leptin. The results showed that betulinic acid could represent a candidate to cure obesity through changes in fat and carbohydrate metabolisms [63].

Several in vitro and in vivo studies have shown that natural triterpenes such as lupeol, betulin, ursolic acid, and oleanolic acid are successful in reducing hepatotoxicity caused by carbon tetrachloride, acetaminophen, ethanol, and cadmium [64–66]. In vitro, betulinic acid has been shown to be a powerful antioxidant agent, which can suppress ethanol-induced activation of hepatic stellate cells mostly by the repression of reactive oxygen species (ROS) and tumor necrosis factor-α (TNF-α) [67]. In the in vivo experiments performed by Yi et al., the authors have highlighted the hepatoprotective effects of betulinic acid, when given orally (0.25, 0.5, and 1.0 mg/kg daily for 14 days) to Kunming mice with induced alcoholic liver disease. Betulinic acid increased hepatic glutathione, superoxide dismutase, glutathione peroxidase, and catalase levels, as well as the levels of malondialdehyde, thereby decreasing the liver’s microvesicular steatosis. In addition, the results of the study indicated that betulinic acid-treated mice showed reduced serum levels of triglycerides and total cholesterol, which was attributed to enhanced β-oxidation in the liver and energy consumption. Betulinic acid also reduced the accumulation of visceral adipose tissue in alcohol-treated mice. In particular, this may help prevent secondary complications emerging from elevated levels of hepatic lipids [68].

PT derived from natural products exhibit a wide variety of medicinal properties such as anti-oxidant [69], anti-tumor [70], anti-microbial [71], and anti-inflammatory [72]. It is assumed that the pathways involved in these bioactivities are caused by the regulation of the immune system. The immunomodulatory efficacy of botanical pentacyclic triterpenes extracted from a broad variety of medicinal plant species, based on different in vitro and in vivo experimental models, has been illustrated in several reports [73,74]. In the experiment conducted by Saaby et al., the immunomodulatory effects of various PT obtained from Rosa canina L. have been evaluated in vitro, on lipopolysaccharide (LPS)-activated Mono Mac 6 cells (an in vitro model for human macrophages). The findings showed that oleanolic, betulinic, and ursolic acid mixtures (30:49:21 w/w) inhibit the release of LPS-induced IL-6 in a stronger manner than individual compounds, with an IC50 value of 21 µmol/L [75]. In the study conducted by Ayatollahi et al., the authors investigated the impact of three phytocompounds (betulinic acid, oleanolic acid and ursolic acid), extracted from Euphorbia microisciadia Boiss, on T-cell proliferation. The T-lymphocytes were isolated from healthy volunteers and analysed using a liquid scintillation counter. Studies have shown that oleanolic acid induces T cell proliferation even at the concentration of 0.5 µg/mL. These findings indicated that oleanolic acid has an important immunostimulating action at very low concentration. Betulinic acid and ursolic acid, on the other hand, were able to suppress the proliferation of T cells with IC50 values above 50 µg/mL and 3 µg/mL, respectively [76]. Marquez-Martin et al. observed that, at concentrations of 10, 25, 50, and 100 µmol/L, some PT extracted from ‘orujo’ olive oil such as oleanolic acid and erythrodiol dose-dependently decreased the secretion of IL-1β and IL-6 isolated from peripheral mononuclear blood cells (PBMCs) of healthy volunteers. Erythrodiol exhibited the most potent inhibitory effect (p < 0.05) on the development of IL-1β and IL-6 PBMCs at all doses. At the maximum tested doses (50–100 µM), oleanolic acid substantially (p < 0.05) down-regulated IL-1β and IL-6 release [77].

The molecular mechanisms behind the different biological activities of PT, ranging from inhibition of acute and chronic inflammation, inhibition of tumor cell proliferation,
activation of apoptosis, and suppression of angiogenesis and metastasis, have been identified in various research studies [40,78]. PT modulate a wide range of molecular targets (cytokines; chemokines; reactive oxygen intermediates; oncogenes; inflammatory enzymes; anti-apoptotic proteins; and transcription factors such as NF-κB, STAT3, AP-1, and CREB), which mediate tumor cell proliferation, transformation, invasion, angiogenesis, metastasis, chemoresistance, and radioresistance [78]. Previous studies have demonstrated that PT, in particular betulin, betulonic acid, lupeol, and ursolic acid, have caused apoptosis in various forms of cancer cells by stimulation of the mitochondrial pathway (intrinsic pathway) rather than the death receptor pathway (extrinsic way) [79,80].

Betulonic acid is highly promising due to its low toxicity in healthy cells and strong anti-proliferative effects against human melanoma cells (IC$_{50}$ = 1.5–1.6 µg/mL) [81,82]; neuroblastoma (IC$_{50}$ = 14–17 µg/mL); medulloblastoma (IC$_{50}$ = 3–13.5 µg/mL); Ewing’s sarcoma; leukemia; brain-tumors; glioblastoma (IC$_{50}$ = 2–17 µg/mL); colon carcinoma; ovarian cancer (IC$_{50}$ = 1.8–4.5 µg/mL); lung cancer (IC$_{50}$ = 1.5–4.2 µg/mL); breast, prostate, head and neck squamous cell carcinoma and hepatocellular; and renal and cervical cancers (IC$_{50}$ = 1.8 µg/mL) [34]. In addition, cell death via the endoplasmic reticulum pathway and ROS-mediated mitochondrial pathway was observed in cervix adenocarcinoma cells (HeLa) treated with betulinic acid [83–85]. In nude mice xenografts bearing estrogen receptor-negative MDA-MB-231 cells, betulinic acid has prevented tumor growth by decreasing the expression of mRNA of Sp transcription factors, which control the expression of genes responsible for cancer growth (SP1, SP3, SP4, VEGFR, and miRNA-27) [86]. In another research study, betulinic acid along with vincristine was able to inhibit lung metastases in an experimental model including B16F10 murine melanoma cells injected in C57BL/6 mice strain [87].

Betulonic acid extracted from Toona sinensis (A Juss.) M.Roem and Belamcanda chinensis L. at 20 µmol/L has shown substantial antitumor activity against various types of cancer cells: human gastric cancer cell line MGC-803 (Inhibitory rate = 56% for Toona sinensis (A Juss.) and 68% for Belamcanda chinensis L.), prostatic cancer cell line PC3 (Inhibitory rate = 63% for Toona sinensis Juss and 52% for Belamcanda chinensis L.), and breast cancer cell line MCF-7 (Inhibitory rate = 51% for Toona sinensis Juss and 56% for Belamcanda chinensis L.) [83,88]. This antitumor activity includes the potential of betulonic acid to cause apoptosis through the mitochondrial signalling cascade, which involves the expression of caspases 3 and 9 and proteins p53 and Bax [83].

3. Betulonic Acid and Its Derivatives. An Overview of In Vitro and In Vivo Active Compounds

Betulin (lup-20(29)-ene-3β,28-diol) and betulonic acid (lup-20(29)-en-3-oxo-28-oic) (Figure 2) are the most important pentacyclic lupane-structure triterpenoids of natural origin. These compounds are found in a broad range of medicinal plants, but they are often extracted from birch bark through sublimation or extraction with organic solvents including ethanol, acetone, and chloroform [37,89]. Betulonic acid has a keto group at C-3 and a carboxyl group at C-28, with a terminal double bond at C-29; the only structural difference compared to betulinic acid lies at the C-3 position where betulonic acid bears a ketone instead of a β-configured hydroxyl [83].

Betulaceae family is the richest source of betulin, with the most important representatives being Betula alba L., Betula pendula Roth, Betula pubescens Ehrh. and Betula platyphylla Suk. [90]. Betulin has also been found in various species of the genera Syzygium (Myrtaceae) [91], Doliocarpus (Dilleniaceae) [92], Paeonia (Paeoniaceae) [93], and Ziziphus (Rhamnaceae) [94], being extracted from bark, leaves, roots, twigs, and fruits. Betulonic acid was traditionally isolated from the fruit of Liquidambar formosana Hance trees with an abundance of 13.4% [95].

The content of betulonic acid in plants is generally low, so it is frequently obtained by a semisynthetic process, which consists in the oxidation of betulin (Figure 2), the main constituent (22–30%) found in the outer part of birch bark [80].
Betulonic acid and its derivatives have been found to possess several medicinal properties, such as anti-viral [96–98], antimicrobial [99,100], anti-Human cytomegalovirus (HCMV) [3], anti-inflammatory [101–103] antioxidant [104], hepatoprotective [103,105], immunostimulant [106], and anticancer effects [107,108]. Modern research has proved that natural products and their semisynthetic variants may serve as the starting point of new drug candidates with a diversity of biological and pharmacological activities. From 1981–2014, natural products accounted for 25% of all newly licensed medicines [109,110]. Betulonic acid is an example of a natural compound that was found to be a promising candidate as an antitumor agent since it can inhibit the growth of different types of tumor cell lines [83]. Betulonic acid is soluble in organic solvents, but its solubility in water is weak. Chemical modifications are used to obtain derivatives with higher bioavailability and special selectivity to cellular targets [111]. Several derivatives were synthesized and examined against different cancer cell lines for antitumor activity (Table 1).

Figure 2. Semi-synthesis of betulonic acid.

Table 1. Betulonic acid derivatives.

| Number | Derivative | Substituent | Reference |
|--------|------------|-------------|-----------|
| I      | ![Betulin](image) | $R = (\text{CH}_2)_2\text{COOH}$ (A) $R = (\text{CH}_2)_8\text{COOH}$ (B) $R = (\text{CH}_2)_10\text{COOH}$ (C) $R = (\text{CH}_2)_8\text{CONHCH(Ph)CH}_2\text{COOH}$ (D) | [112] |
| II     | ![Betulonic acid](image) | $n = 2$ (A) $n = 3$ (B) | [113] |
| Number | Derivative | Substituent | Reference |
|--------|------------|-------------|-----------|
| III    | ![Derivative III](image) | R = (CH₂)₇COOH (A)  
R = (CH₂)₈COOH (B)  
R = (CH₂)₁₀COOH (C)  
R = (CH₂)₈CONHCH(Ph)CH₂COOH (D) | [113] |
| IV     | ![Derivative IV](image) | R = C₆H₅ (A)  
R = 3-F-C₆H₄ (B) | [113] |
| V      | ![Derivative V](image) | R = NH₂ | [114] |
| VI     | ![Derivative VI](image) | R = NH₂  
R = O₂N | [114] |
| VII    | ![Derivative VII](image) | R = NH₂  
R = O₂N | [114] |
| Number | Derivative | Substituent | Reference |
|--------|-----------|-------------|-----------|
| VIII   | ![Image](image1) | ![Substituent](image2) | [114]     |
| IX     | ![Image](image3) | ![Substituent](image4) | [3]       |
| X      | ![Image](image5) | ![Substituent](image6) | [3]       |
| XI     | ![Image](image7) | ![Substituent](image8) | [3]       |
| XII    | ![Image](image9) | ![Substituent](image10) | [115]     |
| Number | Derivative | Substituent | Reference |
|--------|------------|-------------|-----------|
| XIII   | ![Image](image1.png) | R = COOEt (A)  
R = C₆H₅ (B)  
R = 3,4-OMe-C₆H₅ (C)  
R = 2-F-3-Cl-6-CF₃-C₆H₂ (D)  
R = 4-Br-C₆H₄ (E)  
R = Py-4-yl (F) | [116] |
| XIV    | ![Image](image2.png) | R = COOEt (A)  
R = C₆H₅ (B)  
R = 3,4-OMe-C₆H₅ (C)  
R = 2-F-3-Cl-6-CF₃-C₆H₂ (D)  
R = 4-Br-C₆H₄ (E)  
R = Py-4-yl (F) | [117] |
| XV     | ![Image](image3.png) | R = COOEt (A)  
R = C₆H₅ (B)  
R = 3,4-OMe-C₆H₅ (C)  
R = 2-F-3-Cl-6-CF₃-C₆H₂ (D)  
R = 4-Br-C₆H₄ (E)  
R = Py-4-yl (F) | [117] |
| XVI    | ![Image](image4.png) | | [118] |
| XVII   | ![Image](image5.png) | | [118] |
| Number | Derivative | Substituent | Reference |
|--------|------------|-------------|-----------|
| XVIII  | ![Derivative XVIII](image) | ![Substituent XVIII](image) | [119] |
| XIX    | ![Derivative XIX](image) | ![Substituent XIX](image) | [119] |
| XX     | ![Derivative XX](image) | ![Substituent XX](image) | [119] |
| XXI    | ![Derivative XXI](image) | ![Substituent XXI](image) | [119] |
| XXII   | ![Derivative XXII](image) | ![Substituent XXII](image) | [107] |
The group conducted by Shintyapina et al. examined the inhibitory action of selected amides of betulonic acid on the growth and potential apoptosis induction of MT-4, MOLT-4, CEM (lymphoblastic leukemia), and Hep G2 (liver cancer) tumor cell lines. Betulonic acid amides (compounds I (A–D)) inhibited cell growth at low concentrations ([ID$_{50}$] = 4.2–32.0 µg/mL), as shown in Table 2. The length of the methylene moiety (CH$_2$)$_n$ in the amide residue did not affect the inhibitory activity, however, the introduction of the second amide residue increased the inhibition of the tumor cell growth (I (D)). The apoptosis-inducing activity of betulonic acid amides was higher than that of betulonic acid for MT-4 and MOLT-4 cell lines. Thus, the introduction of amide function at the position C28 of PT led to the formation of effective inducers of apoptosis [112].

Table 2. Role of betulonic acid derivatives among various cancer cell lines.

| Compound | Type Cancer Cell Line | Cell Line | In Vitro | Conclusion | Reference |
|----------|----------------------|-----------|----------|------------|----------|
| A        | T-cell leukemia      | MT-4      | [ID$_{50}$] = 25 µg/mL | Betulonic acid amides inhibited growth of tumor cells and induced apoptosis | [112] |
|          |                      | MOLT-4    | [ID$_{50}$] = 10 µg/mL |
|          |                      | CEM       | [ID$_{50}$] = 9 µg/mL |
|          | Liver cancer         | Hep G2    | [ID$_{50}$] = 32 µg/mL |
| I B      | T-cell leukemia      | MT-4      | [ID$_{50}$] = 20 µg/mL | Betulonic acid amides inhibited growth of tumor cells and induced apoptosis | [112] |
|          |                      | MOLT-4    | [ID$_{50}$] = 16 µg/mL |
|          |                      | CEM       | [ID$_{50}$] = 13 µg/mL |
|          | Liver cancer         | Hep G2    | [ID$_{50}$] = 32 µg/mL |
| I C      | T-cell leukemia      | MT-4      | [ID$_{50}$] = 32 µg/mL | |
|          |                      | MOLT-4    | [ID$_{50}$] = 10 µg/mL |
|          |                      | CEM       | [ID$_{50}$] = 8 µg/mL |
|          | Liver cancer         | Hep G2    | [ID$_{50}$] = 32 µg/mL |
| I D      | T-cell leukemia      | MT-4      | [ID$_{50}$] = 4 µg/mL |
|          |                      | MOLT-4    | [ID$_{50}$] = 5 µg/mL |
|          |                      | CEM       | [ID$_{50}$] = 7 µg/mL |
|          | Liver cancer         | Hep G2    | [ID$_{50}$] = 25 µg/mL |
| II A     | Gastric carcinoma    | MGC-803   |          |            |
|          | Prostate carcinoma   | PC3       |          |            |
|          | Breast carcinoma     | Bcap-37   |          |            |
|          | Malignant melanoma   | A375      |          |            |
| II B     | Gastric carcinoma    | MGC-803   |          | Half maximal inhibitory concentration ([IC$_{50}$]) = above 20 µM | [113] |
|          | Prostate carcinoma   | PC3       |          | Antiproliferative activity was significantly reduced |
|          | Breast carcinoma     | Bcap-37   |          | Half maximal inhibitory concentration ([IC$_{50}$]) = above 20 µM |
|          | Malignant melanoma   | A375      |          | Antiproliferative activity was significantly reduced |

[112] Shintyapina et al. (2021).
[113] Shintyapina et al. (2022).
| Compound | Type Cancer Cell Line | Cell Line | In Vitro | Conclusion | Reference |
|-----------|-----------------------|-----------|----------|------------|-----------|
| III       | Gastric carcinoma     | MGC-803   | IC₅₀ ≈ 4 µM | Derivative inhibited cell proliferation and induced cell apoptosis | [113] |
|           | Prostate carcinoma    | PC3       | IC₅₀ ≈ 6 µM |             |           |
|           | Breast carcinoma      | Bcap-37   | IC₅₀ ≈ 4 µM |             |           |
|           | Malignant melanoma    | A375      | IC₅₀ ≈ 8 µM |             |           |
| IV A      | Gastric carcinoma     | MGC-803   | IC₅₀ ≈ 5 µM | Compounds exhibited antiproliferative ability | [113] |
|           | Prostate carcinoma    | PC3       | IC₅₀ ≈ 4 µM |             |           |
|           | Breast carcinoma      | Bcap-37   | IC₅₀ ≈ 7 µM |             |           |
|           | Malignant melanoma    | A375      | IC₅₀ ≈ 6 µM |             |           |
| IV B      | Gastric carcinoma     | MGC-803   | IC₅₀ ≈ 5 µM |             |           |
|           | Prostate carcinoma    | PC3       | IC₅₀ ≈ 7 µM |             |           |
|           | Breast carcinoma      | Bcap-37   | IC₅₀ ≈ 6 µM |             |           |
|           | Malignant melanoma    | A375      | IC₅₀ ≈ 8 µM |             |           |
| V         | Cervix adenocarcinoma | HeLa      | Inhibition percentage (Inhib) = 60% | Compound showed weak cytotoxic activity | [114] |
|           | Skin carcinoma        | A431      | Inhib ≈ 20% |             |           |
|           | Ovarian carcinoma     | A2780     | Inhib ≈ 46% |             |           |
|           | Breast adenocarcinoma | MCF-7     | Inhib ≈ 40% |             |           |
| VI        | Cervix adenocarcinoma | HeLa      | Inhib ≈ 26% |             |           |
|           | Skin carcinoma        | A431      | Inhib ≈ −21% |             |           |
|           | Ovarian carcinoma     | A2780     | Inhib ≈ 51% |             |           |
|           | Breast adenocarcinoma | MCF-7     | Inhib ≈ 29% |             |           |
| VII       | Cervix adenocarcinoma | HeLa      | Inhib ≈ 55% | Compounds revealed a cytotoxic effect on HeLa, A431, A2780, MCF-T tumor cell lines, except for derivatives VI and VIII. They didn’t have cytotoxic activity on the A431 cell line. | [114] |
|           | Skin carcinoma        | A431      | Inhib ≈ 20% |             |           |
|           | Ovarian carcinoma     | A2780     | Inhib ≈ 41% |             |           |
|           | Breast adenocarcinoma | MCF-7     | Inhib ≈ 40% |             |           |
| VIII      | Cervix adenocarcinoma | HeLa      | Inhib ≈ 71% |             |           |
|           | Skin carcinoma        | A431      | Inhib ≈ −6% |             |           |
|           | Ovarian carcinoma     | A2780     | Inhib ≈ 75% |             |           |
|           | Breast adenocarcinoma | MCF-7     | Inhib ≈ 71% |             |           |
| IX        | Murine leukemia        | L1210     | IC₅₀ = 196 µM | Derivative did not inhibit tumor cell proliferation. | [3] |
|           | T-cell leukemia        | CEM       | IC₅₀ = 204 µM |             |           |
|           | Cervix carcinoma       | HeLa      | IC₅₀ = 160 µM |             |           |
Table 2. Cont.

| Compound | Type Cancer Cell Line | Cell Line     | In Vitro | Conclusion                                      | Reference |
|----------|-----------------------|---------------|----------|------------------------------------------------|-----------|
| X        | Murine leukemia       | L1210         | IC₅₀ ≈ 7 µM | Compounds exhibited antiproliferative activity  | [3]       |
|          | T-cell leukemia       | CEM           | IC₅₀ ≈ 3 µM |                                                 |           |
|          | Cervix carcinoma      | HeLa          | IC₅₀ ≈ 7 µM |                                                 |           |
| XI       | Murine leukemia       | L1210         | IC₅₀ ≈ 5 µM |                                                 |           |
|          | T-cell leukemia       | CEM           | IC₅₀ ≈ 1 µM |                                                 |           |
|          | Cervix carcinoma      | HeLa          | IC₅₀ ≈ 9 µM |                                                 |           |
| XI       | Melanoma              | 518A2         | IC₅₀ ≈ 11 µM| Compound presented cytotoxic activity on all tumor cell lines and induced apoptosis on colon cancer cell line | [115]    |
|          | Head and neck tumor   | A253          | IC₅₀ ≈ 11 µM|                                                 |           |
|          | Cervical cancer       | A431          | IC₅₀ ≈ 10 µM|                                                 |           |
|          | Lung cancer           | A549          | IC₅₀ ≈ 11 µM|                                                 |           |
|          | Ovarian cancer        | A2780         | IC₅₀ ≈ 10 µM|                                                 |           |
|          | Colon cancer          | HT-29         | IC₅₀ ≈ 9 µM |                                                 |           |
|          | Breast carcinoma      | MCF-7         | IC₅₀ ≈ 11 µM|                                                 |           |
|          | Anaplastic thyroid tumor | SW1736   | IC₅₀ ≈ 10 µM|                                                 |           |
| XII      | Prostate cancer       | LNCaP         | Inhib ≈ 96% | Compounds exhibited antiproliferative activity  | [116]    |
|          |                       | DU-145        | Inhib ≈ 93% |                                                 |           |
|          |                       | PC3           | Inhib ≈ 77% |                                                 |           |
| XIV A    | Human tumor cells     | CEM-13        | ID₅₀ = 105 µM| Boc-lysinated-betulonic acid inhibited the growth of prostate cancer cells. | [117]    |
|          | T-cell leukemia       | MT-4          | ID₅₀ = 80 µM|                                                 |           |
|          | Human monocytes       | U-937         | ID₅₀ = 33 µM|                                                 |           |
| XIV B    | Human tumor cells     | CEM-13        | ID₅₀ = 72 µM| Betulonic acid hydrazides presented low cytotoxicity | [117]    |
|          | T-cell leukemia       | MT-4          | ID₅₀ = 32 µM|                                                 |           |
|          | Human monocytes       | U-937         | ID₅₀ = 22 µM|                                                 |           |
| XIV C    | Human tumor cells     | CEM-13        | ID₅₀ = 41 µM|                                                 |           |
|          | T-cell leukemia       | MT-4          | ID₅₀ = 44 µM|                                                 |           |
|          | Human monocytes       | U-937         | ID₅₀ = 32 µM|                                                 |           |
| XIV D    | Human tumor cells     | CEM-13        | ID₅₀ = 32 µM| Betulonic acid hydrazides presented the highest cytotoxic activity in several cancer cell lines | [117]    |
|          | T-cell leukemia       | MT-4          | ID₅₀ = 9 µM |                                                 |           |
|          | Human monocytes       | U-937         | ID₅₀ = 12 µM|                                                 |           |
| XIV E    | Human tumor cells     | CEM-13        | ID₅₀ = 35 µM|                                                 |           |
|          | T-cell leukemia       | MT-4          | ID₅₀ = 14 µM|                                                 |           |
|          | Human monocytes       | U-937         | ID₅₀ = 23 µM|                                                 |           |
| XIV F    | Human tumor cells     | CEM-13        | ID₅₀ = 57 µM| Betulonic acid hydrazide presented moderate cytotoxic activity in several cancer cell line | [117]    |
|          | T-cell leukemia       | MT-4          | ID₅₀ = 19 µM|                                                 |           |
|          | Human monocytes       | U-937         | ID₅₀ = 24 µM|                                                 |           |
| Compound | Type Cancer Cell Line | Cell Line  | In Vitro | Conclusion | Reference |
|----------|-----------------------|------------|----------|------------|-----------|
| XV A     | Human tumor cells     | CEM-13     | ID<sub>50 </sub> = 120 µM | The 1,3,4-oxadiazole derivatives with ethoxycarbonyl, phenyl and methoxyphenyl substituents exhibited low cytotoxic activity in several cancer cell lines | [117] |
|          | T-cell leukemia       | MT-4       | ID<sub>50 </sub> = 79 µM  |            |           |
|          | Human monocytes       | U-937      | ID<sub>50 </sub> = 26 µM  |            |           |
| XV B     | Human tumor cells     | CEM-13     | ID<sub>50 </sub> = 63 µM  |            |           |
|          | T-cell leukemia       | MT-4       | ID<sub>50 </sub> = 62 µM  |            |           |
|          | Human monocytes       | U-937      | ID<sub>50 </sub> = 35 µM  |            |           |
| XV C     | Human tumor cells     | CEM-13     | ID<sub>50 </sub> = 52 µM  |            |           |
|          | T-cell leukemia       | MT-4       | ID<sub>50 </sub> = 45 µM  |            |           |
|          | Human monocytes       | U-937      | ID<sub>50 </sub> = 28 µM  |            |           |
| XV E     | Human tumor cells     | CEM-13     | ID<sub>50 </sub> = 33 µM  | The 1,3,4-oxadiazole derivatives with p-bromophenyl or pyridyl substituents exhibited the highest cytotoxic activity | [117] |
|          | T-cell leukemia       | MT-4       | ID<sub>50 </sub> ≈ 11 µM |            |           |
|          | Human monocytes       | U-937      | ID<sub>50 </sub> ≈ 19 µM |            |           |
| XV F     | Human tumor cells     | CEM-13     | ID<sub>50 </sub> = 37 µM  |            |           |
|          | T-cell leukemia       | MT-4       | ID<sub>50 </sub> ≈ 16 µM |            |           |
|          | Human tumor cells     | CEM-13     | ID<sub>50 </sub> ≈ 15 µM |            |           |
| XVI      | Breast carcinoma      | MCF-7      | IC<sub>50 </sub> = 0.3 µM | Betulonic acid C-28-triphenylphosphonium derivatives presented great cytotoxic activity in several cancer cell lines | [118] |
|          | Prostate cancer       | PC-3       | IC<sub>50 </sub> = 0.9 µM |            |           |
| XVII     | Breast carcinoma      | MCF-7      | IC<sub>50 </sub> = 0.9 µM |            |           |
|          | Prostate cancer       | PC-3       | IC<sub>50 </sub> = 0.4 µM |            |           |
| XVIII    | Melanoma              | 518A2      | IC<sub>50 </sub> = 0.5 µM | C(2)-methylene derivative presented cytotoxic activity on all tumor cell lines and also pro-apoptotic activity on SW480 and A549 cell lines | [119] |
|          | Cervical cancer       | A431       | IC<sub>50 </sub> = 0.2 µM |            |           |
|          | Head and neck tumor   | A253       | IC<sub>50 </sub> = 0.4 µM |            |           |
|          |                      | FADU       | IC<sub>50 </sub> = 0.5 µM |            |           |
|          | Lung carcinoma        | A549       | IC<sub>50 </sub> = 0.6 µM |            |           |
|          | Ovarian cancer        | A2780      | IC<sub>50 </sub> = 0.6 µM |            |           |
|          | Colon cancer          | DLD-1      | IC<sub>50 </sub> = 0.4 µM |            |           |
|          |                      | HCT-8      | IC<sub>50 </sub> = 0.2 µM |            |           |
|          |                      | HCT-116    | IC<sub>50 </sub> = 0.2 µM |            |           |
|          |                      | HT-29      | IC<sub>50 </sub> = 0.4 µM |            |           |
|          |                      | SW480      | IC<sub>50 </sub> = 0.4 µM |            |           |
|          | Anaplastic thyroid cancer | 8505c   | IC<sub>50 </sub> = 0.6 µM |            |           |
|          |                      | SW1736     | IC<sub>50 </sub> = 0.4 µM |            |           |
|          | Breast carcinoma      | MCF-7      | IC<sub>50 </sub> = 0.3 µM |            |           |
|          | Liposarcoma           | LIPO       | IC<sub>50 </sub> = 0.6 µM |            |           |
|          | Mouse fibroblasts     | NIH3T3     | IC<sub>50 </sub> = 0.8 µM |            |           |
| XIX      | Melanoma              | 518A2      | IC<sub>50 </sub> ≈ 2 µM | C(2)-methylene derivative presented cytotoxic activity on all tumor cell lines | [119] |
|          | Cervical cancer       | A431       | IC<sub>50 </sub> ≈ 1 µM  |            |           |
|          | Head and neck tumor   | A253       | IC<sub>50 </sub> ≈ 1 µM  |            |           |
|          |                      | FADU       | IC<sub>50 </sub> ≈ 2 µM  |            |           |
|          | Lung carcinoma        | A549       | IC<sub>50 </sub> ≈ 2 µM  |            |           |
|          | Ovarian cancer        | A2780      | IC<sub>50 </sub> ≈ 1 µM  |            |           |
| Compound Type | Cancer Cell Line | Cell Line | In Vitro | Conclusion | Reference |
|---------------|----------------|-----------|----------|------------|-----------|
| Colon cancer  |                | DLD-1     | IC₅₀ ≈ 2 µM |            |           |
|               |                | HCT-8     | IC₅₀ ≈ 2 µM |            |           |
|               |                | HCT-116   | IC₅₀ ≈ 1 µM |            |           |
|               |                | HT-29     | IC₅₀ ≈ 2 µM |            |           |
|               |                | SW480     | IC₅₀ ≈ 2 µM |            |           |
| Anaplastic thyroid cancer | 8505c | IC₅₀ ≈ 2 µM |            |            |           |
|               |                | SW1736    | IC₅₀ ≈ 2 µM |            |           |
| Breast carcinoma | MCF-7 | IC₅₀ ≈ 1 µM |            |            |           |
| Liposarcoma    | LIPO           | IC₅₀ ≈ 2 µM |            |            |           |
| Mouse fibroblasts | NiH3T3 | IC₅₀ ≈ 2 µM |            |            |           |
| XX E Melanoma  |                | 518A2     | IC₅₀ ≈ 4 µM |            |           |
| XX Cervical cancer | A431 | IC₅₀ ≈ 5 µM |            |            |           |
| XX Head and neck tumor | A253 | IC₅₀ ≈ 4 µM |            |            |           |
| XX Lung carcinoma | A549 | IC₅₀ ≈ 5 µM |            |            |           |
| XX Ovarian cancer | A2780 | IC₅₀ ≈ 5 µM |            |            |           |
| Colon cancer  |                | DLD-1     | IC₅₀ ≈ 6 µM |            |           |
|               |                | HCT-8     | IC₅₀ ≈ 9 µM |            |           |
|               |                | HCT-116   | IC₅₀ ≈ 5 µM |            |           |
|               |                | HT-29     | IC₅₀ ≈ 6 µM |            |           |
|               |                | SW480     | IC₅₀ ≈ 5 µM |            |           |
| Anaplastic thyroid cancer | 8505c | IC₅₀ ≈ 5 µM |            |            |           |
|               |                | SW1736    | IC₅₀ ≈ 5 µM |            |           |
| Breast carcinoma | MCF-7 | IC₅₀ ≈ 4 µM |            |            |           |
| Liposarcoma    | LIPO           | IC₅₀ ≈ 5 µM |            |            |           |
| Mouse fibroblasts | NiH3T3 | IC₅₀ ≈ 5 µM |            |            |           |

C (2)-methylene derivative presented a low cytotoxic activity on all tumor cell lines and also pro-apoptotic activity on SW480 and A549 cell lines [119]

C (2)-methylene derivative encapsulated in liposomes had a threefold rise in cytotoxic activity on all tumor cell lines compared to the non-encapsulated one [119]
| Compound | Type | Cancer Cell Line | Cell Line | In Vitro | Conclusion | Reference |
|----------|------|------------------|-----------|---------|------------|-----------|
| XXII     | Lung cancer |                 | A549/ATCC | Survival rate = 0.05% | The 3-hydroxyimino derivative of betulonic acid inhibited the cell growth and caused death of several cancer cell lines | [107] |
|          |     |                  | HOP-62    | Survival rate ≈ 26%   |            |           |
|          |     |                  | NCI-H23   | Survival rate ≈ 17%   |            |           |
|          |     |                  | NCI-H322M | Survival rate ≈ 20%   |            |           |
|          |     |                  | NCI-H460  | Survival rate ≈ 2%    |            |           |
|          |     |                  | NCI-H522  | Survival rate ≈ 7%    |            |           |
|          | Colon cancer |                  | COLO 205  | Survival rate ≈ −58%  |            |           |
|          |     |                  | HCC-2998  | Survival rate ≈ 7%    |            |           |
|          |     |                  | HCT-116   | Survival rate ≈ 5%    |            |           |
|          |     |                  | HCT-15    | Survival rate ≈ 16%   |            |           |
|          |     |                  | HT29      | Survival rate ≈ 13%   |            |           |
|          |     |                  | KM12      | Survival rate ≈ 21%   |            |           |
|          |     |                  | SW-620    | Survival rate ≈ 23%   |            |           |
|          | Leukemia |                  | CCRF-CEM  | Survival rate = 11%   |            |           |
|          |     |                  | HL-60(TB) | Survival rate ≈ −15%  |            |           |
|          |     |                  | K-562     | Survival rate ≈ 5%    |            |           |
|          |     |                  | MOLT-4    | Survival rate ≈ 6%    |            |           |
|          |     |                  | RPMI-8226 | Survival rate ≈ 9%    |            |           |
|          |     |                  | SR        | Survival rate ≈ 6%    |            |           |
|          | Melanoma |                  | LOX IMVI  | Survival rate ≈ 3%    |            |           |
|          |     |                  | MDA-MB-435| Survival rate ≈ 28%   |            |           |
|          |     |                  | SK-MEL-28 | Survival rate ≈ 28%   |            |           |
|          |     |                  | SK-MEL-5  | Survival rate ≈ 15%   |            |           |
|          |     |                  | UACC-257  | Survival rate ≈ 12%   |            |           |
|          |     |                  | UACC-62   | Survival rate ≈ 26%   |            |           |
|          | Breast cancer |                | MCF7      | Survival rate ≈ 2%    |            |           |
|          |     |                  | MDA-MB-231/ATCC | Survival rate ≈ 14% |            |           |
|          |     |                  | T-47D     | Survival rate ≈ 25%   |            |           |
|          |     |                  | MDA-MB-468| Survival rate ≈ 8%    |            |           |
|          | Nervous system cancer | | SF-539  | Survival rate ≈ 22%   |            |           |
|          |     |                  | U251      | Survival rate ≈ 15%   |            |           |
|          | Prostate cancer |                | PC-3      | Survival rate ≈ 26%   |            |           |
|          | Ovarian cancer |                | OVCA-3    | Survival rate ≈ 25%   |            |           |
|          |     |                  | OVCA-8    | Survival rate ≈ 17%   |            |           |
|          |     |                  | NCI/ADR-RES | Survival rate ≈ 14% |            |           |
|          | Renal cancer |                | 786-0     | Survival rate ≈ 32%   |            |           |
|          |     |                  | CAKI-1    | Survival rate ≈ 13%   |            |           |
|          |     |                  | SN12C     | Survival rate ≈ 19%   |            |           |
|          |     |                  | TK-10     | Survival rate ≈ 18%   |            |           |
|          |     |                  | UO-31     | Survival rate ≈ 10%   |            |           |
Yang et al. have pointed towards the in vitro antiproliferative ability of betulonic acid derivatives against A375 (malignant melanoma), PC3 (prostate cancer), MGC-803 (gastric cancer), MCF-7, and Bcap-37 (breast adenocarcinoma) cell lines. The compounds substituted with a bromoalkyl moiety (II (A), II (B)) demonstrated weak antitumor activity compared with the parent compound betulonic acid. Results have shown that (4-(piperidin-1-yl) butyl) 3-oxo-20(29)-lupen-28-oate (III) was one of the most active compounds, presenting IC$_{50}$ values of 3.6–7.8 µM on the five screened cancer cell lines, whereas compounds substituted with fluorophenyl group (IV) exhibited high and moderate antiproliferative activities, as shown in Table 2. (4-(piperidin-1-yl)butyl) 3-oxo-20(29)-lupen-28-oate has also been shown to induce apoptosis of MGC-803 cells via the mitochondrial intrinsic pathway, which include suppression of the expressions p53, Bax, caspase 9, and caspase 3 [113].

In a similar approach, Ledeži et al. described the cytotoxic effects (MTT assay) of four amino derivatives of betulonic acid against certain tumor cell lines, including HeLa (cervix adenocarcinoma), A431 (skin carcinoma), A2780 (ovarian carcinoma) and MCF-7 (breast adenocarcinoma), as shown in Table 2. Guanylhydrazone (V) had lower cytotoxic activity on all cell lines relative to betulin at both tested concentrations (10, 30 mM). The oxime (VI) was found to have strong cytotoxic effects on the A2780 cell line when used at elevated doses, whereas the cytotoxic effect on the A431 cells was almost negligible when the lower concentration was used. The strongest activity manifested at the lowest concentration of butyl imine (VII) occurred on HeLa cell lines, as opposed to the higher concentration that was relevant for A2780 cell line. Moreover, the thiosemicarbazone (VIII) demonstrated significant cytotoxic effects against HeLa, A2780, and MCF-7 cell lines included in this study, having a comparable inhibitory activity to betulin. Regarding the inhibitory activity against A431 cell line, there was no evidence of it [114].

The inhibitory effects of C(2)-C(3)-fused triazine derivatives of betulonic acid on the proliferation of murine leukemia cells (L1210), human cervix carcinoma cells (HeLa), and human T-lymphoblast cells (CEM) were evaluated by Dinh Ngoc et al. The 1,2,4-triazine derivative of betulonic acid (IX) did not elicit a significant cytostatic activity, while S-alkylated triazine derivatives (X, XI) strongly inhibited tumor cell proliferation, especially in case of human T-lymphoblast cells [3].

Kommera et al. demonstrated the in vitro cytotoxic activity of the betulonic acid derivative, 2-amino-3-hydroxy-2-(hydroxymethyl) propyl betulonate (XII), on eight different tumor cell lines: 518A2 (melanoma), A253 (head and neck tumor), A431 (cervical), A2780 (ovarian), A549 (lung), HT-29 (colon), MCF-7 (breast), and SW1736 (anaplastic thyroid tumor) using the sulforhodamine B colorimetric assay. As shown in Table 2, IC$_{50}$ values were found to be in the range of 9.44–10.83 µM. A comparison regarding the cytotoxicity of betulonic acid and compound XII showed a loss of specificity towards some cancer cell lines presented by the parent compound. It has been observed that the derivate also induced apoptosis on HT-29 cell line, which has been confirmed by annexin V staining experiments and DNA fragmentation assay [115].

Following the study conducted by Saxena et al., it has been reported that N-Boc-lysinated-betulonic acid (XIII) elicits positive in vitro effects against prostate cancer cell lines (LNCaP, DU-145, PC-3). The growth of the LNCaP cells was inhibited by lysinated-betulonic acid at 10 µM following 72 h of incubation to 40%, whereas at a concentration of 100 µM, the inhibitory activity increased to 80% (for the compound dissolved in DMSO) and by 96% (for compound dissolved in phosphate-buffered saline [PBS]). Using the MTT assay and various incubation times, the research group showed a significant inhibitory effect on DU-145 and PC-3 cancer cells treated with 100 µM of lysinated-betulonic, as shown in Table 2 [116].

Antimonova et al. have synthesized and evaluated the in vitro cytotoxicity of betulonic acid bearing an 1,3,4-oxadiazole moiety in the C-17 position. The technique used for the preparation of the compounds involved the reaction of acid chlorides (betulonic acid chloride and 3-β-O-acetyl-betulonic acid chloride) with acid hydrazides accompanied by the cyclization of the resulting acylhydrazides (XIV (A–F)) and thus the synthesis of 1,3,4-
oxadiazole derivatives (XV (A–F)). The cytotoxicity against human cancer cell line (MT-4), human T-cell leukemia (CEM-13), and human monocytes (U-937) was determined by MTT assay, and the results were expressed as ID\(_{50}\). Betulonic acid hydrazide (XIV (D)) with a 6-(trifluoromethyl)-2-fluoro-3-chlorophenyl substituent was the most powerful inhibitor of MT-4 (ID\(_{50}\) = 9 \(\mu\)M) and U-937 (ID\(_{50}\) = 12 \(\mu\)M) cells. This compound was slightly more active against U-937 human tumour cells than betulonic acid (ID\(_{50}\) = 19 \(\mu\)M). Regarding the inhibitory activity against the CEM-13 cell line, mild cytotoxicity (ID\(_{50}\) = 32 \(\mu\)M) was noticed compared to betulonic acid (ID\(_{50}\) = 12 \(\mu\)M). The derivative with the substituent 4-Bromophenyl (XIV (E)) was the second hydrazide that has shown great inhibitory activity against MT-4 cell line (ID\(_{50}\) = 14 \(\mu\)M) and moderate cytotoxicity against U-937 and CEM-13 cell lines, with ID\(_{50}\) = 23 \(\mu\)M and ID\(_{50}\) = 23 \(\mu\)M, respectively. On the other hand, hydrazides with phenolic (XIV (B)) and pyridyl (XIV (F)) presented moderate cytotoxicity against MT-4 cell line and U-937 cell line; ID\(_{50}\) values were within 19–32 \(\mu\)M. Concerning the cytotoxicity against the CEM-13 cell line, ID\(_{50}\) values were high (ID\(_{50}\) = 57 \(\mu\)M for derivative (XIV (F)) and 72 \(\mu\)M for derivative (XIV (B)). In contrast, derivatives (XIV (A)) and (XIV (C)) exhibited low cytotoxicity against all cancer cell lines, with ID\(_{50}\) values ranging from 32–105 \(\mu\)M. Among the 1,3,4-oxadiazole derivatives, compounds (XV (E)) and (XV (F)) with \(\rho\)-bromophenyl or pyridyl substituents in the C-5 position had the strongest cytotoxicity against MT-4 (ID\(_{50}\) = 11 \(\mu\)M and ID\(_{50}\) = 16 \(\mu\)M, respectively) and U-937 human cancer cells (ID\(_{50}\) = 17 \(\mu\)M and ID\(_{50}\) = 15 \(\mu\)M, respectively). The cytotoxic activity against CEM-13 cell line was moderate for both oxadiazole derivatives (ID\(_{50}\) = 33 \(\mu\)M for derivative (XV (E)) and ID\(_{50}\) = 37 \(\mu\)M derivative (XV (F)), respectively. Regarding the inhibitory activities of compounds (XV (A–F)), ID\(_{50}\) values were much higher than those of betulonic acid, suggesting that these derivatives had low cytotoxicity (ID\(_{50}\) ranged from 28 to 120 \(\mu\)M) as shown in Table 2.

The cytotoxicity of these compounds was significantly influenced by the nature of the substituents at oxadiazole C-5 [117].

The cytotoxicity of betulonic acid conjugated with triphenylphosphonium salts (TPP) against human breast cancer (MCF-7), human prostate adenocarcinoma (PC-3), and normal human skin fibroblasts (HSF) was studied by Tsepaeva et al. Synthesis of betulonic acid-derived TPP salts was conducted by the reaction of halo alkyl esters with triphenylphosphine. According to MTT assay, after 72 h incubation, 9-triphenylphosphoniononyl 3-oxolup-20(29)-en-28-oate (XX), the authors encapsulated the compound into soybean lecithin liposomes (XX (E)), thus leading to a threefold rise in cytotoxicity. This study has shown that these derivatives have improved the antiproliferative activity on cancer cells and not on normal HSF cells. Such selectivity may be due to the enhanced uptake of triterpenoids by cancer cells, presumably attributable to the TPP moiety [118].
2-methylene-3-oxolup-20(29)en-28-oic acid (XVIII), methyl 2-methylene-3-oxolup-20(29)en-28-oate (XX) and methyl (2α)-2-[(2-hydroxyethyl)thio]methyl]-3-oxolup-20(29)en-28-oate (XXI) were also examined in terms of pro-apoptotic activity; they induced DNA fragmentation in colon cancer cell line SW480, thereby providing strong signs of apoptosis. In addition, acridine orange/ethidium bromide staining of A549 lung carcinoma cells treated with these derivatives also showed induced apoptosis [119].

Kazakova et al. have reported the biological activity of C-28-imidazolides of betulonic acid, containing 3-oxo-, 3-hydroxyimino-, and 2-cyano-2,3-seco-4(23)-ene fragments in cycle A. Firstly, they assessed the cytotoxicity of the imidazolides (cycle A) using different human tumor cell lines (lungs, colon, central nervous system, ovary, renal, prostate, mammary gland, melanoma, leukemia), dyed with sulforhodamine B, and treated with 10 µM of the derivatives for 48 h. The results have shown that the imidazolide of 3-hydroxyimino-lup-20(29)-en-28-carboxylic acid (cycle A) (XXII) was the most efficient in inhibiting the cell growth of all six lung cancer cell lines, all seven large intestine cancer cell lines, all six leukemia cell lines, all six melanoma cell lines, all four breast cancer cell lines, two nervous system cancer cell lines, one prostate cancer cell line, three ovarian cancer cell lines, and five renal cancer cell lines. The cell survival rates are depicted in Table 2. Moreover, cell death was found in three cell lines: lung cancer cell line (NCI-H460), colon cancer cell line (COLO 205), and leukemia cell line (HL-60[TB]) [107]. An overview of the anticancer activity of betulonic acid derivatives is presented in Figure 2.

Owing to the hydrophobic properties of betulonic acid, its in vivo anti-cancer effectiveness has not been intensively studied (Figure 3). In a research performed by Saxena et al., they investigated the in vivo activity of hydrophilic lysinated betulonic acid on LNcaP prostate cancer cells xenografts in athymic mice (Table 3). In contrast to the control group, the lysinated betulonic acid injected mice displayed a 92% inhibition of tumor development. Moreover, histological analyses of the tumors revealed the lack of dividing cells, demonstrating the anticancer activity of the lysinated-betulonic acid [116].

Figure 3. A snap shot of the in vitro and in vivo anticancer effects of the most active derivatives of betulonic acid.
Based on the remarkable results obtained for the imidazolide of 3-hydroxyimino-lup-20(29)-en-28-carboxylic acid (XXII), Kazakova et al. have studied its antineoplastic activity in vivo on two ascites tumors (Ehrlich tumor and P388 lympholeukemia) and three solid tumors (breast adenocarcinoma [Ca755], colon adenocarcinoma [AKATOL], and Lewis lung cancer [LLC]) inoculated in BDF1 hybrids (DBA2 × C57B1/6J), BALB/C, and DBA mice. This chemical derivative injected intraperitoneally, five times daily at a dosage of 70 mg/kg, had no antineoplastic effect neither on the Ehrlich ascites tumor nor P388 lympholeukemia (at a dose of 30 and 50 mg/kg), respectively. Interestingly, the administration of 50 mg/kg through the same procedure suppressed the development of breast adenocarcinoma (Ca755) by 56–77%. The result was maintained without an improvement in life duration until day eight of the study. In mice with large intestinal adenocarcinoma treated by the same procedure, a 53% decrease in tumor growth was seen only after 5 days of therapy without any change in the mice’s lifespan [107].

The research study conducted by Zhukova et al. examined the effects of betulonic acid and its methyl esters derivatives on the pathological modifications in the kidneys of the C57BL/6 mice, presenting Lewis pulmonary adenocarcinoma. Compounds were administered intraperitoneally in a dosage of 50 mg/kg for 8 days. After 8 days, mice were decapitated under ethereal anesthesia and sections of the treated kidneys were analyzed using periodic acid–Schiff reaction-hematoxylin and eosin-orange G dyeing. These chemical derivatives had a beneficial impact on the course of paraneoplastic nephropathy; they decreased the volume density of epithelial cell necrosis at 56%. On average, the number of cells with edematic cytoplasm, vesicular lipid infiltrate, and disrupted brush lymbus fell by 8–13% in comparison to untreated tumoral cells [120].

4. Conclusions

Data presented in this work show that following structural modifications, which involved the introduction of amide, thiol, and piperidine groups, amplification of the in vitro anticancer potential of betulonic acid can be achieved. Studies published in the state of the art literature revealed that betulonic acid derivatives possess an important in vitro cytotoxic and pro-apoptotic activity. However, the number of in vivo studies is limited. The screening of scientific literature on this topic indicates a demand for in-depth in vivo data regarding the effect and mechanism of action of the betulonic acid derivatives in order to benefit from these structures in different therapeutic protocols designated for the management of various types of cancer.
Author Contributions: A.L., A.D.S., S.A., I.Z.P., C.A.D.—screening of the literature, selection of the presented information, writing, original draft preparation; M.T., J.L., U.P., C.S., C.D.—conceptualisation, visualisation, graphic design, review, editing. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by an Internal grant at “Victor Babes” University of Medicine and Pharmacy, Grant 1EXP/1233/30.01.2020 LUPSKINPATH, Project Manager: C.S.; I.J.L. and M.T. thank the ERA.Net RUS Plus project # RUS_ST2017-139 “AnticancerBet” for financial support.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| ACh | Acetylcholine |
| DMSO | Dimethyl sulfoxide |
| DNA | Deoxyribonucleic acid |
| EMA | European Medicines Agency |
| FDA | Food and Drug Administration |
| HeLa | Cervical adenocarcinoma |
| IC<sub>50</sub> | Half maximal inhibitory concentration |
| ID<sub>50</sub> | Compound concentration inhibiting by 50% the tumor-cell viability |
| IL-1β | Interleukin 1 beta |
| IL-6 | Interleukin 6 |
| MDA-MB-231 | Triple-negative breast cancer |
| miRNA-27 | Microrna |
| mRNA | Messenger RNA |
| MTT | 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide |
| PBMC | Peripheral mononuclear blood cells |
| PBS | Phosphate-buffered saline |
| PT | Pentacyclic triterpenoids |
| ROS | Reactive oxygen species |
| SP | Specificity protein |
| SREBP | Sterol regulatory element-binding proteins |
| TNF-α | Tumor Necrosis Factor-α |
| TPP | Triphenylphosphonium |
| VEGFR | Vascular endothelial growth factor |

References

1. Bonofiglio, D.; Giordano, C.; De Amicis, F.; Lanzino, M.; Andò, S. Natural Products as Promising Antitumoral Agents in Breast Cancer: Mechanisms of Action and Molecular Targets. *Mini Rev. Med. Chem.* **2016**, *16*, 596–604. [CrossRef] [PubMed]
2. Bailon-Moscoso, N.; Cevallos-Solorzano, G.; Romero-Benavides, J.; Ramirez Orellana, M. Natural Compounds as Modulators of Cell Cycle Arrest: Application for Anticancer Chemotherapies. *Curr. Genom.* **2017**, *18*, 106–131. [CrossRef]
3. Dinh Ngoc, T.; Moons, N.; Kim, Y.; De Borggraewe, W.; Mashentseva, A.; Andrei, G.; Snoeck, R.; Balzarini, J.; Dehaen, W. Synthesis of Triterpenoid Triazine Derivatives from Allobetulone and Betulonic Acid with Biological Activities. *Bioorg. Med. Chem.* **2014**, *22*, 3292–3300. [CrossRef]
4. Majolo, F.; de Oliveira Becker Delwing, L.K.; Marmitt, D.J.; Bustamante-Filho, I.C.; Goettert, M.I. Medicinal Plants and Bioactive Natural Compounds for Cancer Treatment: Important Advances for Drug Discovery. *Phytochem. Lett.* **2019**, *31*, 196–207. [CrossRef]
5. Matulja, D.; Wittine, K.; Malatesti, N.; Laclef, S.; Turks, M.; Kolympadi, M.; Ambrozic, G.; Marković, D. Marine Natural Products with High Anticancer Activities. *Curr. Med. Chem.* **2020**, *27*, 1243–1307. [CrossRef]
6. Pan, L.; Chai, H.-B.; Kinghorn, A.D. Discovery of New Anticancer Agents from Higher Plants. *Front. Biosci. Schol. Ed.* **2012**, *4*, 142–156. [CrossRef] [PubMed]
7. Bhavana, V.; Sudharshan, S.J.S.; Madhu, D. Natural anticancer compounds and their derivatives in clinical trials. In *Anticancer Plants: Clinical Trials and Nanotechnology*; Akhtar, M., Swamy, M., Eds.; Springer: Singapore, 2017; pp. 51–104.
8. Bennouna, J.; Delord, J.P.; Campone, M.; Nguyen, L. Vinflunine: A New Microtubule Inhibitor Agent. *Clin. Cancer Res.* **2008**, *14*, 1625–1632. [CrossRef]

9. Bates, D.; Eastman, A. Microtubule Destabilising Agents: Far More than Just Antimitotic Anticancer Drugs. *Br. J. Clin. Pharmacol.* **2017**, *83*, 255–268. [CrossRef]

10. Lucas, D.M.; Still, P.C.; Pérez, L.B.; Grever, M.R.; Kinghorn, A.D. Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma. *Curr. Drug Targets*** **2010**, *11*, 812–822. [CrossRef] [PubMed]

11. Martino, E.; Casamassima, G.; Castiglione, S.; Cellupica, E.; Pantalone, S.; Papagni, F.; Rui, M.; Siciliano, A.M.; Collina, S. Vinca Alkaloids and Analouges as Anti-Cancer Agents: Looking Back, Peering Ahead. *Bioorg. Med. Chem. Lett.* **2018**, *28*, 2816–2826. [CrossRef] [PubMed]

12. Gerullis, H.; Wawroschek, F.; Köhne, C.; Ecke, T.H. Vinflunine in the Treatment of Advanced Urothelial Cancer: Clinical Evidence and Experience. *Therap. Adv. Urol*. **2017**, *28*, 36. [CrossRef]

13. World Health Organization. Essential Medicines. Available online: https://www.who.int/topics/essential_medicines/en/ (accessed on 23 February 2021).

14. Chinta, G.; Syed, S.B.; Coumar, M.; Periyasamy, L. Piperine: A Comprehensive Review of Pre-Clinical and Clinical Investigations. *Curr. Bioact. Compd.* **2015**, *11*, 156–169. [CrossRef]

15. Venditto, V.J.; Eric, E. Simanek. Cancer Therapies Utilizing the Camptothecins: A Review of in Vivo Literature. *Biophys. Chem.* **2005**, *257*, 2432–2437. [CrossRef]

16. Choudhari, A.S.; Mandave, P.C.; Deshpande, M.; Ranjekar, P.; Salomone, S. Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice. *Front. Pharmacol.* **2020**, *10*, 1–17. [CrossRef]

17. Wang, X.H.; Zhou, S.Y.; Qian, Z.Z.; Zhang, H.L.; Qiu, L.H.; Song, Z.; Zhao, J.; Wang, P.; Hao, X.S.; Wang, H.Q. Evaluation of Toxicity and Single-Dose Pharmacokinetics of Intravenous Ursolic Acid Liposomies in Healthy Adult Volunteers and Patients with Advanced Solid Tumors. *Expert Opin. Drug Metab. Toxicol.* **2013**, *9*, 117–125. [CrossRef] [PubMed]

18. Ganguly, A.; Yang, H.; Cabral, F. Paclitaxel-Dependent Cell Lines Reveal a Novel Drug Activity. *Mol. Cancer Ther.* **2010**, *9*, 2914–2923. [CrossRef] [PubMed]

19. Priyadarshini, K.; Keerthi, A.U. Paclitaxel Against Cancer: A Short Review. *Med. Chem.* **2019**, *16*, 77–80. [CrossRef] [PubMed]

20. Dastghaib, S.; Khadem, F.; Behrouj, H.; Aghanoori, M.-R.; Machaj, F.; Ghasmari, M.; Rosik, J.; et al. Betulin and Its Derivatives as Novel Compounds with Different Pharmacological Effects. *Biotechnol. Adv.* **2020**, *38*, 107409. [CrossRef]

21. Jiuzhang. Available online: http://en.jiuzhang.com.cn/Productview/54.html (accessed on 7 February 2021).

22. National Library of Medicine (USA). Available online: https://clinicaltrials.gov/ct2/show/results/NCT01882985?view=results (accessed on 23 February 2021).

23. National Library of Medicine (USA). Available online: https://clinicaltrials.gov/ct2/show/NCT03167268 (accessed on 7 February 2021).

24. National Library of Medicine (USA). Available online: https://clinicaltrials.gov/ct2/show/NCT03167268 (accessed on 7 February 2021).

25. National Library of Medicine (USA). Available online: https://clinicaltrials.gov/ct2/show/results/NCT01882985?view=results (accessed on 23 February 2021).

26. National Library of Medicine (USA). Available online: https://clinicaltrials.gov/ct2/show/study/NCT01912820?term=curcumin&cond=cancer&draw=3&rank=12 (accessed on 7 February 2021).

27. National Library of Medicine (USA). Available online: https://clinicaltrials.gov/ct2/show/results/NCT01325311?term=curcumin&cond=Prostate+Cancer&draw=2&rank=9 (accessed on 7 February 2021).

28. National Library of Medicine (USA). Available online: https://clinicaltrials.gov/ct2/show/NCT03769766 (accessed on 7 February 2021).

29. National Library of Medicine (USA). Available online: https://clinicaltrials.gov/ct2/show/NCT03167268 (accessed on 7 February 2021).

30. National Library of Medicine (USA). Available online: https://clinicaltrials.gov/ct2/show/NCT01882985?view=results (accessed on 23 February 2021).

31. National Library of Medicine (USA). Available online: https://clinicaltrials.gov/ct2/show/NCT03167268 (accessed on 7 February 2021).

32. National Library of Medicine (USA). Available online: https://clinicaltrials.gov/ct2/show/NCT01912820?term=curcumin&cond=cancer&draw=3&rank=12 (accessed on 7 February 2021).

33. National Library of Medicine (USA). Available online: https://clinicaltrials.gov/ct2/show/NCT03476330?term=quercetin&cond=cancer&draw=2&rank=2 (accessed on 7 February 2021).

34. National Library of Medicine (USA). Available online: https://clinicaltrials.gov/ct2/show/NCT03476330?term=quercetin&cond=cancer&draw=3&rank=12 (accessed on 7 February 2021).

35. Mierina, I.; Vilskersts, R.; Turks, M. Delivery Systems for Birch-Bark Triterpenoids and Their Derivatives in Anticancer Research. *Curr. Med. Chem.* **2020**, *27*, 1308–1336. [CrossRef]

36. Ghosh, S. Biosynthesis of Structurally Diverse Triterpenes in Plants: The Role of Oxidosqualene Cyclases. *Proc. Indian Natl. Sci. Acad.* **2016**, *82*, 1189–1210. [CrossRef]
37. Jäger, S.; Trojan, H.; Kopp, T.; Laszczysz, M.N.; Scheffler, A. Pentacyclic Triterpene Distribution in Various Plants—Rich Sources for a New Group of Multi-Potent Plant Extracts. *Molecules* 2009, 14, 2016–2031. [CrossRef]

38. Parmar, S.K.; Sharma, T.P.; Airao, V.B.; Bhatt, R.; Aghara, R.; Chavda, S.; So, R.; Ap, G. Neuropharmacological Effects of Triterpenoids. *Phytotherapy Research* 2013, 4, 354–372.

39. Isah, M.B.; Ibrahim, M.A.; Mohammed, A.; Aliyu, A.B.; Masola, B.; Coetzter, T.H.T. A Systematic Review of Pentacyclic Triterpenes and Their Derivatives as Chemotherapeutic Agents against Tropical Parasitic Diseases. *Parasitology* 2016, 143, 1219–1231. [CrossRef] [PubMed]

40. Laszczysz, M.N. Pentacyclic Triterpenes of the Lupane, Oleanane and Ursane Group as Tools in Cancer Therapy. *Planta Med.* 2009, 75, 1549–1560. [CrossRef]

41. Ekman, R. The Suberin Monomers and Triterpenoids from the Outer Bark of Betula Verrucosa Ehrh. *Holzforschung* 1983, 37, 205–211. [CrossRef]

42. Banerjee, S.; Bose, S.; Mandal, S.C.; Dawn, S.; Sahoo, U.; Ramadran, M.A.; Mandal, S.K. Pharmacological Property of Pentacyclic Triterpenoids. *Egypt. J. Chem.* 2019, 62, 13–35. [CrossRef]

43. Laszczysz, M.; Jäger, S.; Simon-Haarrhaus, B.; Scheffler, A.; Scheppm, C.M. Physical and Pharmacological Characterization of a New Oligoel-Forming Triterpene Extract from the Outer Bark of Birch (Betulae Cortex). *Planta Med.* 2006, 72, 1389–1395. [CrossRef] [PubMed]

44. Chudzik, M.; Korzeneck-Szacheta, I.; Król, W. Triterpenes as Potentially Cytotoxic Compounds. *Molecules* 2015, 20, 1610–1625. [CrossRef]

45. Soica, C.; Voicu, M.; Ghiulai, R.; Dehelean, C.; Racoviceanu, R.; Trandafirescu, C.; Roșca, O.-J.; Nistor, G.; Mioc, M.; Mioc, A. Natural Compounds in Sex Hormone-Dependent Cancers: The Role of Triterpenes as Therapeutic Agents. *Front. Endocrinol.* 2021, 11, 1042. [CrossRef] [PubMed]

46. Xiao, S.; Tian, Z.; Wang, Y.; Si, L.; Zhang, L.; Zhou, D. Recent Progress in the Antiviral Activity and Mechanism Study of Pentacyclic Triterpenoids and Their Derivatives. *Med. Res. Rev.* 2018, 38, 951–976. [CrossRef]

47. Lyu, H.; Chen, J.; Li, W.L. Natural Triterpenoids for the Treatment of Diabetes Mellitus: A Review. *Nat. Prod. Commun.* 2016, 11, 1579–1586. [CrossRef]

48. Bai, L.; Meng, F.; Zhao, L.; Zhao, M. The Anti-Inflammatory Activity of Pentacyclic Triterpenes In Vitro. *Appl. Mech. Mater.* 2011, 138–139, 1174–1178. [CrossRef]

49. Wang, C.-M.; Chen, H.-T.; Wu, Z.-Y.; Jian, Y.-L.; Shyu, C.-L.; Chou, C.-H. Antibacterial and Synergistic Activity of Pentacyclic Triterpenoids Isolated from Alstonia Scholaris. *Molecules* 2016, 139. [CrossRef]

50. Bakovic, M. Biologically Active Triterpenoids and Their Cardioprotective and Anti-Inflammatory Effects. *J. Bioanal. Biomed.* 2015, 01. [CrossRef]

51. Prasad, S.; Kalra, N.; Shukla, Y. Hepatoprotective Effects of Lupeol and Mango Pulp Extract of Carcinogen Induced Alteration in Swiss Albino Mice. *Mol. Nutr. Food Res.* 2007, 51, 352–359. [CrossRef]

52. Ghiulai, R.; Roșca, O.J.; Antal, D.S.; Mioc, M.; Mioc, A.; Racoviceanu, R.; Macașoi, I.; Olariu, T.; Dehelean, C.; Crețu, O.M.; et al. Tetracyclic and Pentacyclic Triterpenes with High Therapeutic Efficiency in Wound Healing Approaches. *Molecules* 2020, 25, 5557. [CrossRef] [PubMed]

53. Alqahtani, A.; Hamid, K.; Kam, A.; Wong, K.H.; Abdellahak, Z.; Razmoksi-Naumovski, V.; Chan, K.; Li, K.M.; Groundwater, P.W.; Li, G.Q. The Pentacyclic Triterpenoids in Herbal Medicines and Their Pharmacological Activities in Diabetes and Diabetic Complications. *Curr. Med. Chem.* 2013, 20, 908–931.

54. Zhang, B.W.; Xing, Y.; Wen, C.; Yu, X.X.; Sun, W.L.; Xiu, Z.L.; Dong, Y.S. Pentacyclic Triterpenes as α-Glucosidase and α-Amylase Inhibitors: Structure-Activity Relationships and the Synergism with Acarbose. *Bioorg. Med. Chem. Lett.* 2017, 27, 5065–5070. [CrossRef]

55. Norberg, Å.; Nguyen, K.H.; Liepinsh, E.; Van Phan, D.; Nguyen, D.T.; Jörnvall, H.; Sillard, R.; Östenson, C.G. A Novel Inulin-Releasing Substance, Phanoside, from the Plant Gynostemma Pentaphyllum. *J. Biol. Chem.* 2004, 279, 41361–41367. [CrossRef]

56. Teodor, T.; Zhang, L.; Alexander, T.; Yue, J.; Vranic, M.; Volchuk, A. Oleandronic Acid Enhances Insulin Secretion in Pancreatic Beta-Cells. *FEBS Lett.* 2008, 582, 1375–1380. [CrossRef] [PubMed]

57. Lee, W.-K.; Kao, S.-T.; Liu, I.-M.; Cheng, J.-T. Increase of Insulin Secretion by Ginsenoside Rh2 to Lower Plasma Glucose in Wistar Rats. *Clin. Exp. Pharmacol. Physiol.* 2006, 33, 27–32. [CrossRef]

58. Hsu, J.-H.; Wu, Y.-C.; Liu, I.-M.; Cheng, J.-T. Release of Acetylcholine to Raise Insulin Secretion in Wistar Rats by Oleandronic Acid, One of the Active Priniciples Contained in Cornus Officinalis. *Neurosci. Lett.* 2006, 404, 112–116. [CrossRef] [PubMed]

59. Maneesai, P.; Bunbupha, S.; Kukongviriyapan, U.; Prachaney, P.; Chavda, S.; So, R.; Ap, G. Neuropharmacological Effects of Triterpenoids. *Phytotherapy Research* 2013, 4, 354–372.

60. Prabhakar, P.; Reeta, K.H.; Maulik, S.K.; Dinda, A.K.; Gupta, Y.K. α-Amyrin Attenuates High Fructose Diet-Induced Metabolic Syndrome in Rats. *Appl. Physiol. Nutr. Metab. Physiol.* 2017, 42, 23–32. [CrossRef]

61. Sharma, H.; Kumar, P.; Deshmukh, R.R.; Bishayee, A.; Kumar, S. Pentacyclic Triterpenes: New Tools to Fight Metabolic Syndrome. *Phytomedicine* 2018, 50, 166–177. [CrossRef]
62. Tang, J.J.; Li, J.G.; Qi, W.; Qiu, W.W.; Li, P.S.; Li, B.L.; Song, B.L. Inhibition of SREBP by a Small Molecule, Betulin, Improves Hyperlipidemia and Insulin Resistance and Reduces Atherosclerotic Plaques. Cell Metab. 2011, 13, 44–56. [CrossRef]

63. De Melo, C.L.; Queiroz, M.G.R.; Arruda Filho, A.C.V.; Rodrigues, A.M.; De Sousa, D.F.; Almeida, J.G.L.; Pessoa, O.D.L.; Silveira, E.R.; Menezes, D.B.; Melo, T.S.; et al. Betulinic Acid, a Natural Pentacyclic Triterpenoid, Prevents Abdominal Fat Accumulation in Mice Fed a High-Fat Diet. J. Agric. Food Chem. 2009, 57, 8776–8781. [CrossRef]

64. Zheng, Z.-W.; Song, S.-Z.; Wu, Y.-L.; Lian, L.-H.; Wan, Y.; Nan, J.-X. Betulinic Acid Prevention of D-Galactosamine/Lipopolysaccharide Liver Toxicity Is Triggered by Bcl-2 and Antioxidant Mechanisms. J. Pharm. Pharmacol. 2011, 63, 572–578. [CrossRef] [PubMed]

65. Szuster-Ciesielska, A.; Plewka, K.; Daniluk, J.; Kandefer-Szerszen, M. Protective Effects of Betulin and Betulinic Acid against Ethanol-Induced Liver Stellate Cell Activation by Inhibiting Reactive Oxygen Species (ROS), Cytokine (TNF-α, TGF-β) Production and by Influencing Intracellular Signaling. Toxicology 2011, 280, 152–163. [CrossRef] [PubMed]

66. Sunitha, S.; Nagaraj, M.; Varalakshmi, P. Hepatoprotective Effect of Lupeol and Lupeol Linoleate on Tissue Antioxidant Defence System in Cadmium-Induced Hepatotoxicity in Rats. Fitoterapia 2001, 72, 516–523. [CrossRef]

67. Szuster-Ciesielska, A.; Kandefer-Szerszen, M. Protective Effects of Betulin and Betulinic Acid against Ethanol-Induced Cytotoxicity in HepG2 Cells. Pharmacol. Rep. 2005, 57, 588–595. [PubMed]

68. Yi, J.; Xia, W.; Wu, J.; Yuan, L.; Wu, J.; Tu, D.; Fang, J.; Tan, Z. Betulinic Acid Prevents Alcohol-Induced Liver Damage by Improving the Antioxidant System in Mice. J. Vet. Sci. 2014, 15, 141–148. [CrossRef]

69. Santiago, L.; Dayrit, K.; Correa, P.; Mayor, A.B. Comparison of Antioxidant and Free Radical Scavenging Activity of Triterpenes α-Amyrin, Oleanolic Acid and Ursolic Acid. J. Nat. Prod. 2014, 7, 29–36.

70. Zhang, W.; Men, X.; Lei, P. Review on Anti-Tumor Effect of Triterpene Acid Compounds. J. Cancer Res. Ther. 2014, 10, C14–C19. [CrossRef]

71. Wochiniz, D.; Tichaczeck-Goska, D.; Korzekwa, K.; Kicia, M.; Hendrich, A. Anti-Enterococcal Activities of Pentacyclic Triterpenes. Adv. Clin. Exp. Med. 2017, 26, 483–490. [CrossRef]

72. Lucetti, D.L.; Lucetti, E.C.; Bandeira, M.A.M.; Veras, H.N.; Silva, A.H.; Leal, L.K.A.; Lopes, A.A.; Alves, V.C.; Silva, G.S.; Brito, G.A.; et al. Anti-Inflammatory Effects of Possible Action of Lupeol Acetate Isolated from Himatanthus Drasticus (Mart.) Plumel. J. Inflamm. 2010, 7, 60. [CrossRef]

73. Oladimeji, A.O.; Oladosu, I.A.; Jabeen, A.; Faheem, A.; Mesiak, M.A.; Ali, M.S. Immunomodulatory Activities of Isolated Compounds from the Root-Bark of Csucoria Arboarea. Pharm. Biol. 2017, 55, 2240–2247. [CrossRef] [PubMed]

74. Harun, N.H.; Septama, A.W.; Ahmad, W.A.N.W.; Suppian, R. Immunomodulatory Effects and Structure-Activity Relationship of Botanical Pentacyclic Triterpenes: A Review. Chin. Herb. Med. 2020, 12, 118–124. [CrossRef]

75. Saaby, L.; Jäger, A.K.; Moesby, L.; Hansen, E.W.; Christensen, S.B. Isolation of Immunomodulatory Triterpene Acids from a Standardized Rose Hip Powder (Rosa canina L.). Phytother. Res. 2011, 25, 195–201. [CrossRef]

76. Ayatollahi, A.M.; Ghanadian, M.; Afsharpyour, S.; Abdolla, O.M.; Mirzai, M.; Askari, G. Pentacyclic Triterpenes in Euphorbia Microscia with Their T-Cell Proliferation Activity. Iran. J. Pharm. Res. 2011, 10, 287–294.

77. Marquez-Martin, A.; De La Puerta, R.; Fernandez-Arche, A.; Ruiz-Gutierrez, V.; Yaqoob, P. Modulation of Cytokine Secretion by Pentacyclic Triterpenes from Olive Pomace Oil in Human Mononuclear Cells. Cytokine 2006, 36, 211–217. [CrossRef] [PubMed]

78. Shanmugam, M.K.; Nguyen, A.H.; Kumar, A.P.; Tan, B.K.H.; Sethi, G. Targeted Inhibition of Tumor Proliferation, Survival, and Metastasis by Pentacyclic Triterpenoids: Potential Role in Prevention and Therapies of Cancer. Cancer Lett. 2012, 320, 158–170. [CrossRef] [PubMed]

79. Mullauer, F.B.; Kessler, J.H.; Medema, J.P. Betulin Is a Potent Anti-Tumor Agent That Is Enhanced by Cholesterol. PLoS ONE 2009, 4, e1. [CrossRef]

80. Zhang, X.; Hu, J.; Chen, Y. Betulinic Acid and the Pharmacological Effects of Tumor Suppression (Review). Mol. Med. Rep. 2016, 14, 4489–4495. [CrossRef]

81. Tan, Y.; Yu, R.; Pezzuto, J.M. Betulinic Acid-Induced Programmed Cell Death in Human Melanoma Cells Involves Mitogen-Activated Protein Kinase Activation. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2003, 9, 2866–2875.

82. Zuco, V.; Supino, R.; Righetti, S.C.; Cleris, L.; Marchesi, E.; Gambacorti-Passerini, C.; Formelli, F. Selective Cytotoxicity of Betulinic Acid on Tumor Cell Lines, but Not on Normal Cells. Cancer Lett. 2002, 175, 17–25. [CrossRef]

83. Yang, S.; Zhao, Q.; Xiang, H.; Liu, M.; Zhang, Q.; Xue, W.; Song, B.; Yang, S. Antiproliferative Activity and Apoptosis-Inducing Mechanism of Constituents from Toona Sinensis on Human Cancer Cells. Cancer Cell Int. 2013, 13, 1. [CrossRef] [PubMed]

84. Gheorgheous, D.; Duicu, O.; Dehelean, C.; Soica, C.; Muntean, D. Betulinic Acid as a Potent and Complex Antitumor Phytochemical: A Minireview. Anticancer Agents Med. Chem. 2014, 14, 936–945. [CrossRef] [PubMed]

85. Ali-Seyed, M.; Jantan, I.; Vijayaraghavan, K.; Bukhari, S.N.A. Betulinic Acid: Recent Advances in Chemical Modifications, Effective Delivery, and Molecular Mechanisms of a Promising Anticancer Therapy. Chem. Biol. Drug Des. 2016, 87, 517–536. [CrossRef] [PubMed]

86. Mertens-Talcott, S.U.; Noratto, G.D.; Li, X.; Angel-Morales, G.; Bertoldi, M.C.; Safe, S. Betulinic Acid Decreases ER-Negative Breast Cancer Cell Growth In Vitro and In Vivo: Role of Sp Transcription Factors and MicroRNA-27a:ZBTB10. Mol. Carcinog. 2013, 52, 591–602. [CrossRef]
111. Sbârclea, L.; Ledeți, A.; Udrescu, L.; Vâruț, R.M.; Barvinschi, P.; Vlase, G.; Ledeți, I. Betulonic Acid—Cyclodextrins Inclusion Complexes. *J. Therm. Anal. Calorim.* 2019, 138, 2787–2797. [CrossRef]

112. Shintyapina, A.B.; Shults, E.E.; Petrenko, N.I.; Uzenkova, N.V.; Tolstikov, G.A.; Pronkina, N.V.; Kozhevnikov, V.S.; Pokrovsky, A.G. Effect of Nitrogen-Containing Derivatives of the Plant Triterpenes Betulin and Glycyrrhetic Acid on the Growth of MT-4, MOLT-4, CEM, and Hep G2 Tumor Cells. *Russ. J. Bioorg. Chem.* 2007, 33, 579–583. [CrossRef]

113. Yang, S.J.; Liu, M.C.; Zhao, Q.; Hu, D.Y.; Xue, W.; Yang, S. Synthesis and Biological Evaluation of Betulonic Acid Derivatives as Antitumor Agents. *Eur. J. Med. Chem.* 2015, 96, 58–65. [CrossRef]

114. Ledeți, I.; Avram, Ş.; Bercean, V.; Vlase, G.; Vlase, T.; Ledeți, A.; Zupko, I.; Mioc, M.; Šuta, L.M.; Șoica, C.; et al. Solid-State Characterization and Biological Activity of Betulonic Acid Derivatives. *Molecules* 2015, 20, 22691–22702. [CrossRef]

115. Kommera, H.; Kaluderović, G.N.; Kalbitz, J.; Dräger, B.; Paschke, R. Small Structural Changes of Pentacyclic Lupane Type Triterpenoid Derivatives Lead to Significant Differences in Their Anticancer Properties. *Eur. J. Med. Chem.* 2010, 45, 3346–3353. [CrossRef]

116. Saxena, B.B.; Zhu, L.; Hao, M.; Kisilis, E.; Kadtare, M.; Oktem, O.; Bomshteyn, A.; Rathnam, P. Boc-Lysinated-Betulonic Acid: A Potent, Anti-Prostate Cancer Agent. *Bioorg. Med. Chem.* 2006, 14, 6349–6358. [CrossRef] [PubMed]

117. Antimonova, A.N.; Petrenko, N.I.; Shakirov, M.M.; Pokrovskii, M.A.; Pokrovskii, A.G.; Shuil’s, E.E. Synthesis and Cytotoxic Activity of Lupane Triterpenoids Containing 1,3,4-Oxadiazoles. *Chem. Nat. Compd.* 2014, 50, 1016–1023. [CrossRef]

118. Tsepaeva, O.V.; Nemtarev, A.V.; Salikhova, T.I.; Abdullin, T.I.; Grigor’eva, L.R.; Khozyainova, S.A.; Mironov, V.F. Synthesis, Anticancer, and Antibacterial Activity of Betulinic and Betulonic Acid C-28-Triphenylphosphonium Conjugates with Variable Alkyl Linker Length. *Anticancer Agents Med. Chem.* 2019, 20, 286–300. [CrossRef] [PubMed]

119. Csuk, R.; Stark, S.; Nitsche, C.; Barthel, A.; Stiewert, B. Alkylidene Branched Lupane Derivatives: Synthesis and Antitumor Activity. *Eur. J. Med. Chem.* 2012, 53, 337–345. [CrossRef] [PubMed]

120. Zhukova, N.A.; Sorokina, I.V.; Tolstikova, T.G.; Dolgikh, M.P.; Semenov, D.E. Effect of Betulonic Acid and Its Derivatives on the Morphology of Kidneys in the Animals with Transplanted Lewis Lung Carcinoma at the Background of Polychemotherapy and without It. *Chem. Sustain. Dev.* 2010, 18, 403–408.